Design: Randomized, double-blind, placebo-controlled Phase 2 trial
This publication has not received compensated product samples for testing, has not interviewed brand personnel, has not been granted access to internal specifications beyond what is publicly published, and has not conducted laboratory or clinical testing of any RxSpan MD product or service
Increased thirst is not listed as a common adverse effect in the FDA-approved prescribing information for GLP-1 receptor agonists
For the dataset of the tirzepatideGLP-1RG s Nb35 complex, automated particle selection yielded 4,213,140 particles, which were subjected to reference-free 2D classification, producing 668,880 particles with well-defined averages
Common adverse effects include gastrointestinal symptoms, particularly nausea (30-50% of patients), vomiting, diarrhea, and constipation
Regional markets continued shaping demand dynamics